Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Leukemia may affect red blood cells, white blood cells, and platelets. There are different subtypes of AML, most AML subtypes are based on how mature the cancer cells are at the time of diagnosis and how different they are from normal cells. Acute promyelocytic leukemia (APL) is a subtype of AML that occurs when parts of two genes stick together. APL usually occurs in middle-aged adults. Signs of APL may include both bleeding and forming blood clots. Acute myeloid leukemia (AML) has many other names, including acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.
Acute Myeloid Leukemia Market Outlook
The global acute myeloid leukemia market is observing significant growth owing to high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development and increasing investments in R&D by the pharmaceutical companies. The market is further boosted by global rise in the incidence of AML, along with increased mortality due to the disease. In addition, increasing per capita income is enabling people to take up advanced procedures, thus driving the growth of this market. Active role of healthcare agencies and government in creating awareness about various diseases is also expected to facilitate the growth of acute myeloid leukemias, thereby supporting market development. However, the market is hindered by complications related to chemotherapy and stringent regulations on drugs.
Acute Myeloid Leukemia Market Segmental Overview
The report analyses the global acute myeloid leukemia market based on indication, treatment type, end user and geography.
Acute Myeloid Leukemia Market by Indication
Based on indication, the market is categorized into undifferentiated acute myeloblastic, acute myeloblastic leukemia with minimal maturation, acute myeloblastic leukemia with maturation, acute promyelocytic leukemia (APL), acute myelomonocytic leukemia, acute myelomonocytic leukemia with eosinophilia, acute monocytic leukemia, acute erythroid leukemia and acute megakaryoblastic leukemia. Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin's lymphoma, as well as meningeal leukemia and other types of lymphoma.
Acute Myeloid Leukemia Market by Treatment Type
The acute myeloid leukemia market offers treatment types including chemotherapy, radiation therapy, stem cell transplant, targeted therapy and other treatment types. Stem cell transplants are most often used to help people with leukemia and lymphoma. They may also be used for neuroblastoma and multiple myeloma. The high doses of cancer treatment before a stem cell transplant can cause problems such as bleeding and an increased risk of infection.
Acute Myeloid Leukemia Market by End User
Furthermore, various end users of this market are categorized into hospitals, ambulatory surgical centers, oncology centers and clinics. The hospitals comprise surgical units based in hospitals or attached to hospitals that are equipped with instruments and accessories, to perform procedures for diagnostic or treatment of acute myeloid leukemia.
Acute Myeloid Leukemia Market by Geography
By geography, the global acute myeloid leukemia market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. In 2018, North America held the largest revenue share mainly due to factors such as government support for quality healthcare, high purchasing power parity, availability of reimbursement, and increasing prevalence of cancers in U.S. and Canada. Furthermore, Asia Pacific is expected to witness lucrative growth over the forecast period owing to supportive government initiatives and improving healthcare infrastructure. Additionally, economic developments in countries, such as India and China, are expected to help spur the market growth. Huge population base with low per capita income in the region led to high demand for affordable treatment options.
Acute Myeloid Leukemia Market Key Players
The leading acute myeloid leukemia market players are Bristol Myer Squibb, Celegene Corporation, Eisai Co. Ltd., Genmab A/S, Novartis AG, Pfizer Inc, Sanofi-Aventis (Genzyme Corporation), Sunesis and Teva Pharmaceutical (Cephalon Inc.). For instance, August 2017, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval of BESPONSA (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
